SCHEMBL29655424

SCHEMBL29655424

Cn1cc(CCNC(=O)OC(C)(C)C)c2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
RAB9A P51151 1/20 0.53
KDM4E B2RXH2 2/20 0.52
TP53 P04637 3/20 0.50
NQO2 P16083 2/20 0.50
HPGD P15428 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HTR2A P28223 1/20 0.49
LMNA P02545 2/20 0.48
MTNR1A P48039 1/20 0.48
MTNR1B P49286 1/20 0.48
HDAC6 Q9UBN7 4/20 0.48
HDAC3 O15379 3/20 0.48
HDAC4 P56524 3/20 0.48
HDAC1 Q13547 3/20 0.48
HDAC7 Q8WUI4 3/20 0.48
HDAC2 Q92769 3/20 0.48
HDAC10 Q969S8 3/20 0.48
HDAC8 Q9BY41 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14550631 1.00 KMT2A (0.53) KMT2AMEN1RAB9AKDM4ETP53
SCHEMBL21614239 0.87 KDM4E (0.60) KMT2AMEN1RAB9AKDM4ETP53
SCHEMBL14550636 0.87 NQO2 (0.47) KMT2AMEN1RAB9AKDM4ENQO2
SCHEMBL14550601 0.86 HDAC10 (0.52) KMT2AMEN1TP53NQO2HDAC6
SCHEMBL14550620 0.86 HDAC10 (0.52) KMT2AMEN1TP53NQO2HDAC6
SCHEMBL14550793 0.85 HDAC10 (0.53) KMT2AMEN1TP53NQO2LMNA
SCHEMBL30721515 0.85 L3MBTL1 (0.60) KMT2AMEN1NQO2LMNAHDAC6
SCHEMBL22131235 0.85 L3MBTL1 (0.60) KMT2AMEN1NQO2LMNAHDAC6
SCHEMBL21614223 0.85 NR4A2 (0.51) KMT2AMEN1RAB9ANQO2MTNR1A
SCHEMBL21614208 0.84 CDK2 (0.48) KMT2AMEN1RAB9ATP53NQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 EP disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 US disclosed
US-11787783-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-10-17 US disclosed
CN-110831600-B Indole AHR inhibitors and uses thereof 医肯纳肿瘤学公司 2023-10-17 CN disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 KMT2A 622/4885MEN1 4767/4885RAB9A 4560/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 KMT2A 622/4885MEN1 4767/4885RAB9A 4560/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 KMT2A 622/4885MEN1 4767/4885RAB9A 4560/4885
US-11787783-B2 Heparanase inhibitors and use thereof HPSE, HEXD, ENGASE KMT2A 3905/4885MEN1 3249/4885RAB9A 1264/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 KMT2A 622/4885MEN1 4767/4885RAB9A 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.